Affordable Access

Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.

Authors
Type
Published Article
Journal
The Journal of clinical psychiatry
Publication Date
Volume
64
Issue
10
Pages
1245–1249
Identifiers
PMID: 14658975
Source
Medline
License
Unknown

Abstract

The selective GABA reuptake inhibitor tiagabine and the positive control paroxetine significantly reduced anxiety and comorbid depressive symptoms, improved sleep quality and functioning, and were well tolerated in patients with GAD. Tiagabine may be a therapeutic option for the treatment of anxiety disorders.

Statistics

Seen <100 times